Auto-reactions, autoimmunity and psoriatic arthritis

Chimenti, Maria Sole; Triggianese, Paola; Nuccetelli, Marzia; Terracciano, Chiara; Crisanti, Anna; Guarino, Maria Domenica; Bernardini, Sergio; Perricone, Roberto

doi:10.1016/j.autrev.2015.08.003

Cited by 51 publications

(45 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Importantly, we found that the levels of both anti–ADAMTS‐L5 and anti–LL‐37 autoantibodies were significantly elevated in patients with PsA compared to non‐PsA controls, suggesting that these molecules may be involved in the pathogenesis of PsA. This is consistent with previous findings showing that autoantibodies may be associated with PsA . Furthermore, the autoantibodies against ADAMTS‐L5 or LL‐37 could be used as biomarkers to discriminate PsA from non‐PsA.…”

Section: Discussionsupporting

confidence: 91%

Identification of Novel Autoantibodies Associated With Psoriatic Arthritis

Yuan

Qiu

Lin

et al. 2019

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective. The autoimmune etiology in psoriasis remains to be clarified. We therefore undertook this study to identify novel pathogenic autoantigens and autoantibodies in patients with psoriasis, with the aim of shedding light on the molecular and cellular basis of the pathogenesis of psoriasis and psoriatic arthritis (PsA).Methods. In this study, we developed an autoantigen array system that harbors a variety of antigens, including typical autoantigens in rheumatic diseases as well as skin antigens, inflammatory mediators, and putative autoantigens in psoriasis. Serum samples from patients with psoriasis (n = 73) were used to interrogate the antigens on the array. In addition, enzyme-linked immunosorbent assays of individual autoantibodies were used in validation studies.Results. Levels of several autoantibodies were found to be elevated in the serum of patients with psoriasis compared to healthy controls; in particular, IgG autoantibodies against 2 novel antigens, LL-37 and ADAMTS-L5, were significantly increased in patients with psoriasis. Importantly, serum levels of IgG autoantibodies against LL-37 and ADAMTS-L5 were correlated with the Psoriasis Area and Severity Index, and reflected disease progression in longitudinally collected serum samples from patients with psoriasis. Importantly, both anti-ADAMTS-L5 and anti-LL-37 autoantibody levels were also significantly elevated in psoriasis patients with PsA compared to those without PsA, suggesting that these molecules may be involved in the pathogenesis of PsA.Conclusion. Our findings indicate that these identified autoantibodies may be useful biomarkers and may serve as therapeutic targets in psoriasis and PsA.

show abstract

Section: Discussionsupporting

confidence: 91%

Identification of Novel Autoantibodies Associated With Psoriatic Arthritis

Yuan

Qiu

Lin

et al. 2019

Arthritis & Rheumatology

View full text Add to dashboard Cite

show abstract

“…Psoriatic arthritis (PsA) is a chronic inflammatory arthropathy seronegative for RF, and associated with psoriasis [150]. PsA is classified among the SpA group because it shares with SpA several clinical manifestations as peripheral and axial joints involvement (arthritis, spondylitis, and sacro-ileitis), skin and nail diseases, dactylitis and enthesitis [151]. The overall prevalence of PsA has been reported to range from 0.01% (95% CI 0.00-0.17) in the Middle East to 0.19% (95% CI 0/16-0.32) in Europe [152].…”

Section: Autoantibodies In Psoriatic Arthritismentioning

confidence: 99%

“…We previously reported an abnormal distribution of peripheral blood B cell in both RA and PsA patients suggesting a role of B cells in PsA pathogenesis [166]. An autoimmune model describing potential autoantigens in the skin and joints of PsA patients has not been identified so far [151]. PsA is distinguished from RA by infrequent positivity for RF and ACPA, together with other distinctive clinical features [167,168].…”

Section: Autoantibodies In Psoriatic Arthritismentioning

confidence: 99%

“…They identified the modulation of cluster of genes encoding for molecules involved in cell migration and tissue invasion, in neoangiogenesis, in the process of bone formation, and in a T cell immune response with prevalent up-regulation of several Th17-related genes [182]. Anti-CarP antibodies were reported in sera from PsA patients with active disease in the absence of RF and/or ACPA specificities [151]. In accordance with such evidence, the measurement of anti-CarP antibodies shows a good Table 2 Prevalence of several autoantibodies in the sera of patients with Psoriatic Arthritis.…”

Section: Autoantibodies In Psoriatic Arthritismentioning

confidence: 99%

See 1 more Smart Citation

Autoantibodies in inflammatory arthritis

Conigliaro

Chimenti

Triggianese

et al. 2016

Autoimmunity Reviews

102

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease characterized by extensive synovitis resulting in erosions of articular cartilage and marginal bone with joint destruction. The lack of immunological tolerance in RA represents the first step toward the development of autoimmunity. Susceptible individuals, under the influence of environmental factors, such as tobacco smoke, and silica exposure, develop autoimmune phenomena that result in the presence of autoantibodies. HLA and non-HLA haplotypes play a major role in determining the development of specific autoantibodies differentiating anti-citrullinated antibodies (ACPA)-positive and negative RA patients. Rheumatoid factor (RF) and ACPA are the serological markers for RA, and during the preclinical immunological phase, autoantibody titers increase with a progressive spread of ACPA antigens repertoire. The presence of ACPA represents an independent risk factor for developing RA in patients with undifferentiated arthritis or arthralgia. Moreover, anti-CarP antibodies have been identified in patients with RA as well as in individuals before the onset of clinical symptoms of RA. Several autoantibodies mainly targeting post-translational modified proteins have been investigated as possible biomarkers to improve the early diagnosis, prognosis and response to therapy in RA patients. Psoriatic arthritis (PsA) is distinguished from RA by infrequent positivity for RF and ACPA, together with other distinctive clinical features. Actually, specific autoantibodies have not been described. Recently, anti-CarP antibodies have been reported in sera from PsA patients with active disease. Further investigations on autoantibodies showing high specificity and sensibility as well as relevant correlation with disease severity, progression, and response to therapy are awaited in inflammatory arthritides

show abstract

“…The assay has since been optimized, and it is included among the revised 2010 classification criteria for RA 10. Recently a new autoantibody system was reported, and anti-carbamylated protein (anti-CarP) antibodies have been identified in RA patients 11. These autoantibodies have been associated with a worse disease progression independent of ACPAs.…”

Section: Introductionmentioning

confidence: 99%

ACPAs Are Much More Than Diagnostic Autoantibodies

Watad

Amital

2016

Rambam Maimonides Med J

View full text Add to dashboard Cite

Anti-citrullinated protein autoantibodies (ACPAs) are the major autoantibodies in rheumatoid arthritis (RA). Anti-citrullinated protein autoantibodies are directed against different citrullinated antigens, including filaggrin, fibrinogen, vimentin, and collagen. Presence of ACPA is associated with joint damage and extra-articular manifestations, suggesting that ACPAs are most likely pathogenic autoantibodies in RA. In vitro, ACPAs induce macrophage tumor necrosis factor alpha (TNF-α) production, osteoclastogenesis, and complement activation. These autoantibodies also induce the formation of neutrophil extracellular traps (NETs). Additionally, ACPAs induce pathogenic cytokines expression and oxidative stress in immune cells derived from RA patients. The aim of this review is to show the pathogenic roles of these autoantibodies in RA.

show abstract

Auto-reactions, autoimmunity and psoriatic arthritis

Cited by 51 publications

References 43 publications

Identification of Novel Autoantibodies Associated With Psoriatic Arthritis

Identification of Novel Autoantibodies Associated With Psoriatic Arthritis

Autoantibodies in inflammatory arthritis

ACPAs Are Much More Than Diagnostic Autoantibodies

Contact Info

Product

Resources

About